TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia

Cell Stem Cell. 2016 May 5;18(5):668-81. doi: 10.1016/j.stem.2016.03.002. Epub 2016 Mar 24.

Abstract

Fanconi anemia (FA) is an inherited DNA repair disorder characterized by progressive bone marrow failure (BMF) from hematopoietic stem and progenitor cell (HSPC) attrition. A greater understanding of the pathogenesis of BMF could improve the therapeutic options for FA patients. Using a genome-wide shRNA screen in human FA fibroblasts, we identify transforming growth factor-β (TGF-β) pathway-mediated growth suppression as a cause of BMF in FA. Blocking the TGF-β pathway improves the survival of FA cells and rescues the proliferative and functional defects of HSPCs derived from FA mice and FA patients. Inhibition of TGF-β signaling in FA HSPCs results in elevated homologous recombination (HR) repair with a concomitant decrease in non-homologous end-joining (NHEJ), accounting for the improvement in cellular growth. Together, our results suggest that elevated TGF-β signaling contributes to BMF in FA by impairing HSPC function and may be a potential therapeutic target for the treatment of FA.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetaldehyde / toxicity
  • Animals
  • Bone Marrow / pathology*
  • Cell Survival / drug effects
  • DNA End-Joining Repair / drug effects
  • Down-Regulation / drug effects
  • Fanconi Anemia / pathology*
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / pathology*
  • Homologous Recombination / genetics
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Mutagens / toxicity
  • Signal Transduction / drug effects
  • Stress, Physiological / drug effects
  • Transforming Growth Factor beta / antagonists & inhibitors*
  • Transforming Growth Factor beta / metabolism
  • Up-Regulation / drug effects

Substances

  • Mutagens
  • Transforming Growth Factor beta
  • Acetaldehyde